CA2466032A1 - Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques - Google Patents
Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques Download PDFInfo
- Publication number
- CA2466032A1 CA2466032A1 CA002466032A CA2466032A CA2466032A1 CA 2466032 A1 CA2466032 A1 CA 2466032A1 CA 002466032 A CA002466032 A CA 002466032A CA 2466032 A CA2466032 A CA 2466032A CA 2466032 A1 CA2466032 A1 CA 2466032A1
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- controlled
- solid
- agent
- pharmaceutical dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
La présente invention se rapporte à des formes posologiques à libération contrôlée destinées à une administration orale. Cette forme posologique comprend un agent thérapeutique qui est métabolisé dans le tractus gastro-intestinal supérieur en combinaison à un agent à libération contrôlée de manière à être hydrodynamiquement équilibrée afin que, lors du contact avec le fluide gastrique, ladite forme posologique possède une densité apparente inférieure à 1 g/ml et par conséquent s'avère susceptible de flotter dans le fluide gastrique. Cette forme posologique est retenue dans l'estomac pendant le laps de temps lui permettant de libérer sensiblement tous les médicaments qu'elle contient. En outre, cette forme posologique permet une libération du médicament pendant un laps de temps prolongé de sorte que l'administration de l'agent thérapeutique à l'intestin grêle se déroule de manière régulière plutôt que subite. Cette libération régulière dans le temps de l'agent thérapeutique au niveau du site de métabolisation et d'absorption permet d'empêcher une saturation enzymatique et favorise par conséquent une meilleure biodisponibilté de l'agent thérapeutique.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01125761 | 2001-10-29 | ||
EP01125761.5 | 2001-10-29 | ||
PCT/EP2002/012062 WO2003037296A2 (fr) | 2001-10-29 | 2002-10-29 | Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2466032A1 true CA2466032A1 (fr) | 2003-05-08 |
Family
ID=8179102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002466032A Abandoned CA2466032A1 (fr) | 2001-10-29 | 2002-10-29 | Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1439820A2 (fr) |
JP (1) | JP2005509643A (fr) |
AU (1) | AU2002351798A1 (fr) |
CA (1) | CA2466032A1 (fr) |
MX (1) | MXPA04004035A (fr) |
WO (1) | WO2003037296A2 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007048219A3 (fr) * | 2005-09-09 | 2007-07-19 | Labopharm Inc | Composition medicamenteuse a liberation prolongee |
US7988998B2 (en) | 2002-10-25 | 2011-08-02 | Labopharm Inc. | Sustained-release tramadol formulations with 24-hour efficacy |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5355002B2 (ja) | 2008-09-10 | 2013-11-27 | オリンパスメディカルシステムズ株式会社 | 浮き量合否判定システム、浮き量合否判定用表示システム、浮き量合否判定方法および浮き量合否判定用表示方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT998271E (pt) * | 1997-06-06 | 2005-10-31 | Depomed Inc | Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis |
PL346798A1 (en) * | 1998-09-14 | 2002-02-25 | Ranbaxy Lab Ltd | Orally administered controlled drug delivery system providing temporal and spatial control |
AP2002002410A0 (en) * | 1999-08-04 | 2002-03-31 | Ranbaxy Laboratories Ltd | Hydrodynamically Balancing Oral Drug Delivery System |
WO2001058424A1 (fr) * | 2000-02-09 | 2001-08-16 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Composition flottante de liberation de medicament |
-
2002
- 2002-10-29 EP EP02787522A patent/EP1439820A2/fr not_active Withdrawn
- 2002-10-29 AU AU2002351798A patent/AU2002351798A1/en not_active Abandoned
- 2002-10-29 CA CA002466032A patent/CA2466032A1/fr not_active Abandoned
- 2002-10-29 MX MXPA04004035A patent/MXPA04004035A/es unknown
- 2002-10-29 WO PCT/EP2002/012062 patent/WO2003037296A2/fr not_active Application Discontinuation
- 2002-10-29 JP JP2003539640A patent/JP2005509643A/ja not_active Withdrawn
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7988998B2 (en) | 2002-10-25 | 2011-08-02 | Labopharm Inc. | Sustained-release tramadol formulations with 24-hour efficacy |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
WO2007048219A3 (fr) * | 2005-09-09 | 2007-07-19 | Labopharm Inc | Composition medicamenteuse a liberation prolongee |
US7829120B2 (en) | 2005-09-09 | 2010-11-09 | Labopharm Inc. | Trazodone composition for once a day administration |
US8795723B2 (en) | 2005-09-09 | 2014-08-05 | Angelini Pharma Inc. | Sustained drug release compositions |
US9439866B2 (en) | 2005-09-09 | 2016-09-13 | Angelini Pharma, Inc. | Trazodone composition for once a day administration |
Also Published As
Publication number | Publication date |
---|---|
EP1439820A2 (fr) | 2004-07-28 |
AU2002351798A1 (en) | 2003-05-12 |
WO2003037296A2 (fr) | 2003-05-08 |
JP2005509643A (ja) | 2005-04-14 |
WO2003037296A3 (fr) | 2003-12-24 |
MXPA04004035A (es) | 2004-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Singh et al. | Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention | |
AU608208B2 (en) | Therapeutic agents | |
Dehghan et al. | Gastroretentive drug delivery systems: A patent perspective | |
Kotreka et al. | Gastroretentive floating drug-delivery systems: a critical review | |
US7674480B2 (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
Gopalakrishnan et al. | Floating drug delivery systems: A Review | |
AU774957B2 (en) | Hydrodynamically balancing oral drug delivery system | |
ES2200166T3 (es) | Comprimido farmaceutico de liberacion controlada que contiene un soporte a base de amilosa reticulada e hidroxipropilmetilcelulosa. | |
CA2412490A1 (fr) | Composition a expansion rapide pour retention gastrique et liberation regulee d'agents therapeutiques, et formes posologiques renfermant cette composition | |
AU2001268722A1 (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
EP1509208A1 (fr) | Equilibrage hydrodynamique de systeme de delivrance de medicaments administres oralement, par liberation biphasique | |
EA012377B1 (ru) | Твёрдые пероральные фармацевтические композиции для введения один раз в сутки, содержащие прегабалин, матрицеобразующий агент и агент набухания | |
US20020119192A1 (en) | Controlled release formulations for oral administration | |
CA2466032A1 (fr) | Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques | |
US20030138486A1 (en) | Methods and dosage forms for improving the bioavailability of therapeutic agents | |
Bhoyar et al. | An overview of a gastro retentive floating drug delivery system | |
Sabale et al. | Formulation and Evaluation of Floating Dosage Forms: An Overview. | |
Katakam et al. | Floating drug delivery systems: a review | |
Kumar et al. | A systematic review on floating drug delivery system | |
Honkanen | Biopharmaceutical evaluation of orally and rectally administered hard hydroxypropyl methylcellulose capsules | |
Tutunji | Development of a gastroretentive controlled release metformin delivery system | |
Mercy et al. | FORMULATION AND EVALUATION OF GASTRORETENTIVE FLOATING IN-SITU GEL OF MINOCYCLINE HCL | |
Rao et al. | A CONCISE REVIEW ON FLOATING DRUG DELIVERY SYSTEM | |
CN1582903A (zh) | 酶降解依赖型结肠定位释药柱塞胶囊及其制备方法 | |
TWI229609B (en) | Pharmaceutical composition of orally administered controlled drug delivery system providing temporal and spatial control |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |